Thursday, March 21, 2024
| 7:00 AM – 8:00 AM | Germline BRCA Mutation Testing in Breast Cancer to Help Inform Clinical Decisions AstraZeneca Industry Forum Georgia World Congress Center (GWCC), Room C108 |
| 7:00 AM – 8:00 AM | An Adjuvant Treatment Option for Certain Patients with Melanoma After Complete Resection Merck Industry Forum GWCC, Room C109 |
| 10:15 AM – 10:35 AM | Tumor-informed Residual Disease (MRD) Testing to Guide Perioperative Decisions in Solid Tumors Natera Industry Spotlight GWCC, SSO HUB |
| 12:15 PM – 12:35 PM | Getting to NOPAIN: Enhancing outcomes with Advanced Pain Management Techniques to Allow for Migration to the Hospital Outpatient Setting Pacira Biosciences Industry Spotlight GWCC, SSO HUB |
| 2:40 PM – 3:00 PM | EnVision: Tailored Precision for Every Patient, Every Time. Elucent Medical Industry Spotlight GWCC, SSO HUB |
Friday, March 22, 2024
| 11:15 AM – 11:35 AM | Please join us for a presentation on OGSIVEO (nirogacestat), the first and only FDA-approved therapy for adult patients with progressing desmoid tumors who require systemic treatment. SpringWorks Therapeutics Industry Spotlight GWCC, SSO HUB |
| 2:45 PM – 3:05 PM | The Role of Oncolytic Immunotherapy in Oncology: Focus on Melanoma Replimune Industry Spotlight GWCC, SSO HUB |
| 5:15 PM – 6:15 PM | A New Treatment Option: Adjuvant Nivolumab Following Complete Resection for Stage IIB/C Melanoma Bristol Myers Squibb Industry Forum GWCC, Room C108 |